Belite Bio, Inc
BLTE
Cena:
$ 137.30
-6.95 (-4.82%)
Valuace
70
Růst
0
Zdraví
75
Akcionáři
Akcionáři společnosti
Insider trading
Akcionáři společnosti
| Držitel | Počet akcií | Podíl společnosti | Změna % | Váha pozice v portfoliu | Prvně nakoupeno |
|---|---|---|---|---|---|
| DARWIN GLOBAL MANAGEMENT, LTD. | 3.1 mil | 9.12% | 2.24% | 12.10% | 2025-12-31 |
| PARADIGM BIOCAPITAL ADVISORS LP | 1.1 mil | 3.32% | 3.63% | 3.63% | 2026-03-31 |
| UBS GROUP AG | 768.36 tis | 2.29% | 0.02% | 0.02% | 2024-09-30 |
| RTW INVESTMENTS, LP | 715.33 tis | 2.13% | -0.01% | 1.13% | 2025-09-30 |
| MILLENNIUM MANAGEMENT LLC | 570.09 tis | 1.70% | 0.00% | 0.04% | 2025-09-30 |
| HOLOCENE ADVISORS, LP | 494.50 tis | 1.47% | 0.16% | 0.19% | 2025-12-31 |
| RA CAPITAL MANAGEMENT, L.P. | 432.48 tis | 1.30% | -0.09% | 0.71% | 2025-09-30 |
| EVENTIDE ASSET MANAGEMENT, LLC | 357.65 tis | 1.07% | -0.01% | 0.94% | 2025-09-30 |
| VESTAL POINT CAPITAL, LP | 312.50 tis | 0.96% | 1.04% | 1.04% | 2025-09-30 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 304.01 tis | 0.91% | 0.09% | 0.57% | 2025-12-31 |
| POINT72 ASSET MANAGEMENT, L.P. | 284.44 tis | 0.86% | 0.05% | 0.05% | 2025-06-30 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 281.81 tis | 0.84% | 0.01% | 0.01% | 2026-03-31 |
| MORGAN STANLEY | 201.41 tis | 0.60% | 0.00% | 0.00% | 2022-09-30 |
| MARSHALL WACE, LLP | 192.70 tis | 0.58% | 0.01% | 0.03% | 2023-12-31 |
| PERCEPTIVE ADVISORS LLC | 151.98 tis | 0.45% | -0.71% | 0.47% | 2025-09-30 |
| PATIENT SQUARE CAPITAL LP | 116.68 tis | 0.35% | 3.30% | 3.30% | 2026-03-31 |
| DUQUESNE FAMILY OFFICE LLC | 106.10 tis | 0.32% | 0.50% | 0.50% | 2026-03-31 |
| GOLDMAN SACHS GROUP INC | 105.51 tis | 0.31% | 0.00% | 0.00% | 2025-09-30 |
| BIOIMPACT CAPITAL LLC | 88.05 tis | 0.26% | -0.52% | 1.08% | 2025-12-31 |
| AFFINITY ASSET ADVISORS, LLC | 65.00 tis | 0.19% | 0.35% | 0.54% | 2025-12-31 |
| FRED ALGER MANAGEMENT, LLC | 62.57 tis | 0.19% | -0.01% | 0.04% | 2025-12-31 |
| WESTERN STANDARD LLC | 60.03 tis | 0.18% | 4.43% | 4.43% | 2025-12-31 |
| PFM HEALTH SCIENCES, LP | 59.43 tis | 0.18% | 0.55% | 0.86% | 2025-12-31 |
| RENAISSANCE TECHNOLOGIES LLC | 52.00 tis | 0.16% | 0.01% | 0.01% | 2025-06-30 |
| EVERSOURCE WEALTH ADVISORS, LLC | 43.25 tis | 0.13% | 0.05% | 0.06% | 2025-06-30 |
| SOLEUS CAPITAL MANAGEMENT, L.P. | 40.35 tis | 0.12% | -0.54% | 0.24% | 2025-09-30 |
| LONGAEVA PARTNERS L.P. | 33.49 tis | 0.10% | 0.20% | 0.20% | 2026-03-31 |
| TD ASSET MANAGEMENT INC | 33.41 tis | 0.10% | 0.00% | 0.00% | 2026-03-31 |
| BNP PARIBAS ARBITRAGE, SNC | 32.53 tis | 0.10% | 0.00% | 0.00% | 2024-12-31 |
| ADAR1 CAPITAL MANAGEMENT, LLC | 26.88 tis | 0.08% | -0.22% | 0.25% | 2025-12-31 |
| ARTIA GLOBAL PARTNERS LP | 24.99 tis | 0.07% | 0.42% | 0.88% | 2025-12-31 |
| SUPERSTRING CAPITAL MANAGEMENT LP | 24.70 tis | 0.07% | 2.12% | 2.12% | 2025-12-31 |
| QUADRATURE CAPITAL LTD | 23.71 tis | 0.07% | 0.00% | 0.05% | 2025-09-30 |
| AQUATIC CAPITAL MANAGEMENT LLC | 20.29 tis | 0.06% | 0.09% | 0.09% | 2025-09-30 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 19.60 tis | 0.06% | 0.00% | 0.00% | 2026-03-31 |
| WOODLINE PARTNERS LP | 18.04 tis | 0.05% | 0.01% | 0.01% | 2025-12-31 |
| SQUAREPOINT OPS LLC | 16.98 tis | 0.05% | 0.00% | 0.00% | 2026-03-31 |
| STATE STREET CORP | 16.05 tis | 0.05% | 0.00% | 0.00% | 2022-09-30 |
| BANK OF MONTREAL /CAN/ | 15.98 tis | 0.05% | 0.00% | 0.00% | 2025-12-31 |
| XTX TOPCO LTD | 15.06 tis | 0.04% | 0.04% | 0.04% | 2026-03-31 |
| TREXQUANT INVESTMENT LP | 15.07 tis | 0.04% | 0.02% | 0.02% | 2026-03-31 |
| EXOME ASSET MANAGEMENT LLC | 14.33 tis | 0.04% | 1.10% | 1.10% | 2025-12-31 |
| VERDAD ADVISERS, LP | 13.81 tis | 0.04% | 2.48% | 2.48% | 2026-03-31 |
| JANE STREET GROUP, LLC | 12.22 tis | 0.04% | 0.00% | 0.00% | 2025-12-31 |
| BOOTHBAY FUND MANAGEMENT, LLC | 11.90 tis | 0.04% | 0.03% | 0.03% | 2025-12-31 |
| HRT FINANCIAL LP | 10.92 tis | 0.03% | 0.00% | 0.00% | 2025-12-31 |
| BLACKSTONE INC. | 10.69 tis | 0.03% | 0.01% | 0.01% | 2026-03-31 |
| GEODE CAPITAL MANAGEMENT, LLC | 10.43 tis | 0.03% | 0.00% | 0.00% | 2023-09-30 |
| JPMORGAN CHASE & CO | 9.81 tis | 0.03% | 0.00% | 0.00% | 2023-12-31 |
| STEMPOINT CAPITAL LP | 9.16 tis | 0.03% | 0.25% | 0.25% | 2025-12-31 |
| HIGHVISTA STRATEGIES LLC | 8.03 tis | 0.02% | 0.35% | 0.35% | 2026-03-31 |
| VOLEON CAPITAL MANAGEMENT LP | 7.88 tis | 0.02% | 0.03% | 0.03% | 2026-03-31 |
| POLYMER CAPITAL MANAGEMENT (HK) LTD | 7.27 tis | 0.02% | 0.07% | 0.07% | 2025-09-30 |
| BARCLAYS PLC | 6.82 tis | 0.02% | 0.00% | 0.00% | 2025-12-31 |
| WELLINGTON MANAGEMENT GROUP LLP | 6.20 tis | 0.02% | 0.00% | 0.00% | 2025-12-31 |
| ARROWPOINT INVESTMENT PARTNERS (SINGAPORE) PTE. LTD. | 6.00 tis | 0.02% | 0.78% | 0.85% | 2025-12-31 |
| CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 5.00 tis | 0.02% | 0.03% | 0.03% | 2025-09-30 |
| CITADEL ADVISORS LLC | 5.06 tis | 0.02% | 0.00% | 0.00% | 2024-09-30 |
| CUBIST SYSTEMATIC STRATEGIES, LLC | 4.65 tis | 0.01% | 0.00% | 0.00% | 2025-06-30 |
| AMUNDI | 4.21 tis | 0.01% | 0.00% | 0.00% | 2026-03-31 |
| 4.19 tis | 0.01% | 0.05% | 0.28% | 2025-12-31 | |
| BANK OF AMERICA CORP /DE/ | 3.78 tis | 0.01% | 0.00% | 0.00% | 2023-09-30 |
| HIGH NET WORTH ADVISORY GROUP LLC | 3.50 tis | 0.01% | 0.00% | 0.13% | 2025-09-30 |
| Y-INTERCEPT (HONG KONG) LTD | 3.15 tis | 0.01% | 0.01% | 0.01% | 2025-12-31 |
| PRELUDE CAPITAL MANAGEMENT, LLC | 3.12 tis | 0.01% | 0.04% | 0.04% | 2025-12-31 |
| CONVERGENCE FINANCIAL, LLC | 2.97 tis | 0.01% | 0.05% | 0.05% | 2026-03-31 |
| AMERIPRISE FINANCIAL INC | 2.77 tis | 0.01% | 0.00% | 0.00% | 2025-03-31 |
| ENGINEERS GATE MANAGER LP | 2.49 tis | 0.01% | 0.01% | 0.01% | 2026-03-31 |
| YEOMANS CONSULTING GROUP, INC. | 2.40 tis | 0.01% | 0.11% | 0.11% | 2025-12-31 |
| AXQ CAPITAL, LP | 2.37 tis | 0.01% | 0.05% | 0.05% | 2026-03-31 |
| ROYAL BANK OF CANADA | 2.26 tis | 0.01% | 0.00% | 0.00% | 2025-12-31 |
| CITIGROUP INC | 2.14 tis | 0.01% | 0.00% | 0.00% | 2025-03-31 |
| SG AMERICAS SECURITIES, LLC | 2.14 tis | 0.01% | 0.00% | 0.00% | 2025-12-31 |
| VIRTUS INVESTMENT ADVISERS, INC. | 1.88 tis | 0.01% | 0.04% | 0.08% | 2025-03-31 |
| GAMMA INVESTING LLC | 1.76 tis | 0.01% | 0.00% | 0.01% | 2023-12-31 |
| SBI SECURITIES CO., LTD. | 0.05 tis | 0.00% | 0.00% | 0.00% | 2024-12-31 |
| ENTRYPOINT CAPITAL, LLC | 0.00 tis | 0.00% | -0.03% | 0.00% | 2023-12-31 |
| ARMISTICE CAPITAL, LLC | 0.00 tis | 0.00% | -0.14% | 0.00% | 2023-06-30 |
| MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 0.00 tis | 0.00% | 0.00% | 0.00% | 2024-12-31 |
| ALYESKA INVESTMENT GROUP, L.P. | 0.00 tis | 0.00% | -0.02% | 0.00% | 2025-03-31 |
| ADVISORS PREFERRED, LLC | 0.00 tis | 0.00% | -0.01% | 0.00% | 2024-12-31 |
| ADVISOR GROUP HOLDINGS, INC. | 0.00 tis | 0.00% | 0.00% | 0.00% | 2023-12-31 |
| PNC FINANCIAL SERVICES GROUP, INC. | 0.00 tis | 0.00% | 0.00% | 0.00% | 2024-12-31 |
| VIRTUS ETF ADVISERS LLC | 0.00 tis | 0.00% | -0.03% | 0.00% | 2023-12-31 |
| ATRIA WEALTH SOLUTIONS, INC. | 0.00 tis | 0.00% | -0.03% | 0.00% | 2022-06-30 |
| QUANTBOT TECHNOLOGIES LP | 0.00 tis | 0.00% | 0.00% | 0.00% | 2024-12-31 |
| TOWER RESEARCH CAPITAL LLC (TRC) | 0.00 tis | 0.00% | 0.00% | 0.00% | 2025-03-31 |
| BLACKROCK INC. | 0.00 tis | 0.00% | 0.00% | 0.00% | 2022-12-31 |
| CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | 0.00 tis | 0.00% | -0.01% | 0.00% | 2025-03-31 |
| QUBE RESEARCH & TECHNOLOGIES LTD | 0.00 tis | 0.00% | 0.00% | 0.00% | 2022-06-30 |
| RHUMBLINE ADVISERS | 0.00 tis | 0.00% | 0.00% | 0.00% | 2024-09-30 |
| ROSSBY FINANCIAL, LCC | 0.01 tis | 0.00% | 0.00% | 0.00% | 2025-09-30 |
| JUMP FINANCIAL, LLC | 0.00 tis | 0.00% | -0.01% | 0.00% | 2023-12-31 |
Insider trading
| Jméno | Pozice | Typ transakce | Počet převedených akcií | Průměrná cena akcie | Datum | Počet držených akcií |
|---|---|---|---|---|---|---|
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 9 | 155.25 | 8.5 2026 | 0 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 3 | 154.61 | 8.5 2026 | 9 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 428 | 153.56 | 8.5 2026 | 12 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 226 | 152.45 | 8.5 2026 | 440 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 100 | 156.00 | 7.5 2026 | 666 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 100 | 155.97 | 7.5 2026 | 766 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 240 | 154.41 | 7.5 2026 | 866 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 128 | 153.42 | 7.5 2026 | 1106 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 424 | 152.67 | 7.5 2026 | 1234 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 8 | 151.57 | 7.5 2026 | 1658 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 68 | 158.11 | 6.5 2026 | 1666 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 155 | 157.29 | 6.5 2026 | 1734 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 121 | 156.53 | 6.5 2026 | 1889 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 173 | 155.48 | 6.5 2026 | 2010 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 363 | 154.44 | 6.5 2026 | 2183 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 120 | 153.92 | 6.5 2026 | 2546 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 172 | 157.49 | 5.5 2026 | 2666 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 235 | 156.57 | 5.5 2026 | 2838 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 325 | 155.21 | 5.5 2026 | 3073 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 236 | 154.24 | 5.5 2026 | 3398 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 32 | 153.50 | 5.5 2026 | 3634 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 23 | 160.00 | 4.5 2026 | 3666 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 38 | 159.08 | 4.5 2026 | 3689 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 65 | 158.35 | 4.5 2026 | 3727 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 106 | 157.45 | 4.5 2026 | 3792 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 82 | 156.24 | 4.5 2026 | 3898 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 346 | 155.48 | 4.5 2026 | 3980 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 288 | 154.38 | 4.5 2026 | 4326 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 52 | 153.89 | 4.5 2026 | 4614 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 101 | 158.15 | 1.5 2026 | 4666 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 340 | 157.37 | 1.5 2026 | 4767 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 517 | 156.59 | 1.5 2026 | 5107 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 42 | 155.68 | 1.5 2026 | 5624 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 22 | 158.19 | 30.4 2026 | 5666 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 102 | 157.39 | 30.4 2026 | 5688 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 339 | 156.43 | 30.4 2026 | 5790 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 259 | 155.52 | 30.4 2026 | 6129 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 278 | 154.58 | 30.4 2026 | 6388 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 54 | 162.14 | 29.4 2026 | 6666 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 89 | 161.72 | 29.4 2026 | 6720 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 120 | 160.27 | 29.4 2026 | 6809 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 380 | 159.42 | 29.4 2026 | 6929 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 62 | 158.71 | 29.4 2026 | 7309 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 222 | 157.49 | 29.4 2026 | 7371 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 53 | 156.61 | 29.4 2026 | 7593 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 8 | 155.36 | 29.4 2026 | 7646 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 12 | 154.65 | 29.4 2026 | 7654 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 36 | 164.07 | 28.4 2026 | 7666 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 409 | 163.56 | 28.4 2026 | 7702 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 231 | 162.38 | 28.4 2026 | 8111 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 280 | 161.62 | 28.4 2026 | 8342 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 44 | 160.83 | 28.4 2026 | 8622 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 3 | 162.53 | 27.4 2026 | 8666 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 28 | 161.22 | 27.4 2026 | 8669 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 330 | 160.40 | 27.4 2026 | 8697 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 375 | 159.46 | 27.4 2026 | 9027 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 190 | 158.65 | 27.4 2026 | 9402 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 74 | 157.86 | 27.4 2026 | 9592 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 21 | 169.56 | 24.4 2026 | 9666 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 54 | 168.43 | 24.4 2026 | 9687 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 373 | 167.37 | 24.4 2026 | 9741 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 127 | 166.56 | 24.4 2026 | 10114 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 158 | 165.38 | 24.4 2026 | 10241 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 267 | 164.47 | 24.4 2026 | 10399 |
| Chuang Hao-Yuan | director, officer: Chief Financial Officer | J-Other | 10000 | 0.00 | 23.4 2026 | 205264 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 21 | 173.04 | 23.4 2026 | 10666 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 249 | 172.49 | 23.4 2026 | 10687 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 257 | 171.62 | 23.4 2026 | 10936 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 75 | 170.58 | 23.4 2026 | 11193 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 105 | 169.52 | 23.4 2026 | 11268 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 101 | 168.64 | 23.4 2026 | 11373 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 141 | 167.42 | 23.4 2026 | 11474 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 20 | 166.32 | 23.4 2026 | 11615 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 31 | 165.70 | 23.4 2026 | 11635 |
| Scholl Hendrik Peter | officer: Chief Medical Officer | J-Other | 10000 | 77.40 | 23.4 2026 | 10000 |
| Lin Yu-Hsin | director, officer: Chief Executive Officer | J-Other | 10000 | 0.00 | 23.4 2026 | 182949 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 214 | 167.34 | 22.4 2026 | 11666 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 312 | 166.49 | 22.4 2026 | 11880 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 332 | 165.49 | 22.4 2026 | 12192 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 78 | 164.60 | 22.4 2026 | 12524 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 64 | 163.49 | 22.4 2026 | 12602 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 9 | 168.35 | 21.4 2026 | 12666 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 16 | 167.17 | 21.4 2026 | 12675 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 3 | 166.91 | 21.4 2026 | 12691 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 40 | 165.29 | 21.4 2026 | 12694 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 124 | 164.40 | 21.4 2026 | 12734 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 524 | 163.52 | 21.4 2026 | 12858 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 284 | 162.76 | 21.4 2026 | 13382 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 36 | 163.21 | 20.4 2026 | 14678 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 76 | 162.26 | 20.4 2026 | 14714 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 240 | 161.61 | 20.4 2026 | 14790 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 201 | 160.35 | 20.4 2026 | 15030 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 219 | 159.81 | 20.4 2026 | 15231 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 216 | 158.28 | 20.4 2026 | 15450 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 200 | 163.33 | 20.4 2026 | 13666 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 216 | 162.48 | 20.4 2026 | 13866 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 274 | 161.41 | 20.4 2026 | 14082 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 226 | 160.55 | 20.4 2026 | 14356 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 52 | 159.38 | 20.4 2026 | 14582 |
| MATA NATHAN L. | officer: Chief Scientific Officer | S-Sale | 32 | 158.46 | 20.4 2026 | 14634 |
